Shared on 09 Dec 25

ASTERDM: Upcoming Board Decisions And ESOP Plan Will Drive Bullish Outlook

Analysts have maintained their price target on Aster DM Healthcare at ₹777.44 per share, reflecting continued confidence in the company’s robust revenue growth outlook, stable profit margins, and supportive future earnings multiple. What's in the News Board to meet on November 6, 2025 at 10:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing) Board to consider adoption of Aster DM Healthcare Limited Employee Stock Option Scheme 2025, signaling continued focus on long term employee incentives (company filing) Proposal to approve a new registered office premises in the State of Hyderabad, indicating an administrative and potential strategic relocation (company filing) Board to review changes in the composition of its committees as part of broader governance updates (company filing) Resignation of Non Executive Director Anoop Moopen (DIN:02301362) to be taken up at the meeting, which may alter board dynamics (company filing) Valuation Changes Fair Value: Unchanged at approximately ₹777.44 per share, indicating no revision to the intrinsic value estimate.

Shared on 25 Nov 25

Fair value Increased 9.95%

ASTERDM: Upcoming Board Review And Approved Dividend Will Drive Positive Outlook

Analysts have raised their price target for Aster DM Healthcare from ₹707 to ₹777, citing expectations of stronger revenue growth and improved profit margins in the future. What's in the News Board meeting scheduled for November 6, 2025, to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments) The board will consider the adoption of the Aster DM Healthcare Limited Employee Stock Option Scheme 2025 during the upcoming meeting (Key Developments) Approval of new registered office premises in the State of Hyderabad is on the board meeting agenda (Key Developments) Changes in the composition of committees and the resignation of Non-Executive Director Mr. Anoop Moopen will be considered (Key Developments) Final dividend of INR 1 per equity share approved for the financial year ended March 31, 2025 (Key Developments) Valuation Changes Consensus Analyst Price Target has increased from ₹707.11 to ₹777.44, reflecting a positive adjustment in valuation.

Shared on 06 Nov 25

Fair value Increased 0.38%

ASTERDM: Results Review And Dividend Decision Will Influence Risk Outlook

Analysts have slightly raised their fair value estimate for Aster DM Healthcare from ₹704.44 to ₹707.11. This change reflects subtle adjustments in discount rate, growth expectations, and profitability forecasts.

Shared on 23 Oct 25

Fair value Increased 4.36%

Narrative Update on Aster DM Healthcare Analysts have revised their price target for Aster DM Healthcare upward from ₹675 to ₹704.44, reflecting improved profit margin expectations, even as revenue growth projections have been slightly moderated. What's in the News The company approved a final dividend of INR 1 per equity share for the financial year ended March 31, 2025.

Shared on 09 Oct 25

Fair value Increased 2.43%

Analysts have raised their price target for Aster DM Healthcare from ₹659 to ₹675. They cite significantly improved revenue growth prospects, which offset reduced profit margins and a lower forecast for future price-to-earnings multiples.

Shared on 04 Aug 25

Fair value Increased 6.32%

Despite a notable rise in both the discount rate and future P/E ratio, analysts have increased their fair value estimate for Aster DM Healthcare, with the consensus price target rising from ₹619.80 to ₹659.00. What's in the News Incorporated two wholly owned subsidiaries in Bengaluru: Aster DM Super-Specialty Hospital (Yeswanthpur) and Aster DM Super-Specialty Hospital (Sarjapur), to set up and operate new hospitals.

Shared on 01 May 25

Fair value Increased 6.81%

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 0.019%

AnalystConsensusTarget has decreased revenue growth from 18.4% to 16.1%.

Shared on 02 Apr 25

Fair value Increased 0.89%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Decreased 7.19%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Increased 2.14%

Analysts Raise Aster DM Healthcare Price Target as Profit Margins Improve and Valuation Increases

ASTERDM: Upcoming Board Decisions And ESOP Plan Will Drive Bullish Outlook

ASTERDM: Upcoming Board Review And Approved Dividend Will Drive Positive Outlook

ASTERDM: Results Review And Dividend Decision Will Influence Risk Outlook

Shared on 23 Oct 25

Shared on 09 Oct 25

Shared on 04 Aug 25

Shared on 01 May 25

Shared on 23 Apr 25

Shared on 17 Apr 25

Shared on 09 Apr 25

Shared on 02 Apr 25

Shared on 26 Mar 25

Shared on 19 Mar 25

Shared on 12 Mar 25